HC Wainwright Issues Negative Estimate for Zynex Earnings

Zynex, Inc. (NASDAQ:ZYXIFree Report) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Zynex in a research report issued on Wednesday, March 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.20) for the quarter, down from their prior forecast of $0.07. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Zynex’s current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Zynex’s Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.40) EPS.

Zynex (NASDAQ:ZYXIGet Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11). Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $45.98 million for the quarter, compared to analysts’ expectations of $53.65 million. During the same period last year, the firm earned $0.04 earnings per share.

A number of other equities analysts have also recently weighed in on the company. Royal Bank of Canada cut Zynex from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $11.00 to $5.50 in a report on Wednesday, March 12th. LADENBURG THALM/SH SH lowered shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th.

Get Our Latest Research Report on ZYXI

Zynex Trading Up 2.4 %

ZYXI opened at $2.97 on Monday. The business’s 50 day moving average price is $7.42 and its 200 day moving average price is $7.91. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The stock has a market capitalization of $94.78 million, a PE ratio of 19.80 and a beta of 0.81. Zynex has a one year low of $2.77 and a one year high of $13.19.

Hedge Funds Weigh In On Zynex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYXI. Hotchkis & Wiley Capital Management LLC boosted its holdings in Zynex by 24.7% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares during the period. GSA Capital Partners LLP raised its position in Zynex by 72.7% in the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after purchasing an additional 33,649 shares in the last quarter. Lido Advisors LLC purchased a new position in shares of Zynex in the 4th quarter valued at about $240,000. Geode Capital Management LLC grew its position in shares of Zynex by 6.7% during the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock worth $3,473,000 after buying an additional 26,774 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Zynex during the fourth quarter worth approximately $211,000. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Insider Activity

In related news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the transaction, the chief financial officer now owns 19,738 shares in the company, valued at approximately $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 30,000 shares of company stock valued at $227,100. 52.13% of the stock is currently owned by corporate insiders.

Zynex Company Profile

(Get Free Report)

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.

Read More

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.